“…The risk of adverse outcomes when deprescribing, such as withdrawal effects, can be minimised or prevented through appropriate patient engagement, planning, tapering, monitoring and clinical handover. 17 , 18 , 20 , 29 , 30 If there are other prescribers involved in the patient’s care (e.g. a cardiologist), they should also be engaged in deprescribing decisions.…”